Posted: 9/29/2012 8:11:58 AM
5.Even if Medivation finally hits a homerun, with Enzalutamide ultimately achieving blockbuster status, the company already boasts a market cap that approaches the $4 billion value placed on the future market for prostate cancer therapies as a whole. Since Medivation must split any revenue generated by Envalutamide with a funding partner, however, its market cap theoretically reflects only half of the overall value assigned to its only product. In other words, investors have effectively pegged the full value of Enzalutamide above the projected value of the entire market for prostate cancer drugs.
6.Medivation cannot even target most of the patients included in that market for a while, either, with the company seeking initial approval of Enzalutamide only for those who have previously failed chemotherapy. While Medivation clearly expects to expand beyond that limited niche -- which accounts for just one-third of the estimated market overall -- the company must first secure official approval before it can actively promote its drug to that larger crowd.
7. Aragon pharma this is a huge threat.
Both drugs originate from novel compounds discovered in the laboratory of acclaimed medical researcher Dr. Charles Sawyers, who actually views the competing drug ARN-509 -- nicknamed the "Son of Medivation" -- as the more promising of the two.It came out later than MDV3100 and is more potent, and has a better safety profile.
Aragon's drug is in phase 2 at the current moment with phase 1 showing very promising results this one product could dethrone medivation just as badly as dndn was dethroned by medivation.